Morphine

Generic Name: Morphine

Brand Names: Arymo, Avinza, Doloral, Duramorph, Embeda, Infumorph, Kadian, M-ediat, M-eslon, MSIR, Mitigo, Ms Contin, Statex

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₁₉NO_₃

CAS Number: 57-27-2

Unique Ingredient Identifier: 76I7G6D29C

Background: Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as codeine, fentanyl, methadone, hydrocodone, hydromorphone, meperidine, and oxycodone.

Morphine was granted FDA approval in 1941.

Indication: Morphine is used for the management of chronic, moderate to severe pain.

Opiods, including morphine, are effective for the short term management of pain. Patients taking opioids long term may need to be monitored for the development of physical dependence, addiction disorder, and drug abuse.

Associated Conditions: Chronic Pain, Severe Pain

Associated Therapies: -

Clinical Trials

Study in Healthy Volunteers to Investigate the Effects of Quinidine on the Pharmacokinetics of NKTR-118

Phase 1

Completed

Conditions: Drug Induced Constipation

Interventions: Drug: Nektar 118
Drug: Quinidine
Drug: Quinidine placebo
Drug: Morphine

First Posted Date: 2012-02-15

Last Posted Date: 2014-10-15

Lead Sponsor: AstraZeneca

Target Recruit Count: 214

Registration Number: NCT01533155

Locations: 🇺🇸
Research Site, Overland Park, Kansas, United States

Perioperative Electroacupuncture on Postoperative Analgesia in Prostatectomy

Phase 4

Completed

Conditions: Pain, Postoperative

Interventions: Drug: Tramadol
Drug: Ketamine
Drug: Morphine
Procedure: sedation
Procedure: rescue analgesia
Drug: Parecoxib
Drug: paracetamol

First Posted Date: 2012-02-06

Last Posted Date: 2014-02-21

Lead Sponsor: G.Gennimatas General Hospital

Target Recruit Count: 70

Registration Number: NCT01526525

Locations: 🇬🇷
G.Gennimatas GENERAL HOSPITAL OF THESSALONIKI, Thessaloniki, Greece

Randomized Double Blind Controlled Trial Comparing a Blind Sciatic Nerve Block in the Popliteal Fossa to Intravenous Morphine for Traumatic Severe Acute Pain in the Prehospital Setting

Phase 3

Terminated

Conditions: Injuries
Pain
Emergencies

Interventions: Drug: Mepivacaine
Drug: Morphine

First Posted Date: 2012-01-31

Last Posted Date: 2019-11-20

Lead Sponsor: Centre Hospitalier Annecy Genevois

Target Recruit Count: 26

Registration Number: NCT01522534

Locations: 🇫🇷
Centre Hospitalier Sallanches Chamonix, Sallanches, France
🇫🇷
Centre Hospitalier Universitaire de GRENOBLE, Grenoble, France
🇫🇷
Centre Hospitalier d'Albertville moutiers, Albertville, France

and more 3 locations

Open-Label, Safety, and Efficacy Study of Dexmedetomidine in Preterm Subjects Ages ≥28 Weeks to <36 Weeks Gestational Age

Phase 2

Completed

Conditions: Anesthesia

Interventions: Drug: Dexmedetomidine
Drug: Midazolam
Drug: Fentanyl
Drug: Morphine

First Posted Date: 2012-01-12

Last Posted Date: 2017-08-23

Lead Sponsor: Hospira, now a wholly owned subsidiary of Pfizer

Target Recruit Count: 6

Registration Number: NCT01508455

A Health Economic Trial in Adult Patients Undergoing Open Colectomy MA402S23B301

Phase 4

Terminated

Conditions: Bowel Obstruction

Interventions: Drug: bupivacaine liposome extended-release injectable suspension
Drug: morphine sulfate

First Posted Date: 2012-01-10

Last Posted Date: 2014-03-06

Lead Sponsor: Pacira Pharmaceuticals, Inc

Target Recruit Count: 2

Registration Number: NCT01507220

Locations: 🇺🇸
The Ohio State University, Columbus, Ohio, United States

Opioid Treatment for Chronic Low Back Pain and the Impact of Mood Symptoms

Phase 4

Completed

Conditions: Chronic Low Back Pain
Anxiety
Depression
Degenerative Disc Disease

Interventions: Drug: Oxycodone
Drug: Morphine
Drug: Placebo

First Posted Date: 2012-01-02

Last Posted Date: 2017-07-11

Lead Sponsor: Brigham and Women's Hospital

Target Recruit Count: 81

Registration Number: NCT01502644

Locations: 🇺🇸
Brigham and Women's Hospital, Chestnut Hill, Massachusetts, United States

Drug Drug Interaction Study With Gabapentin Enacarbil and Morphine

Phase 1

Completed

Conditions: Restless Legs Syndrome

Interventions: Drug: morphine Placebo
Drug: Morphine
Drug: GEn 600 mg
Drug: GEn Placebo

First Posted Date: 2011-11-22

Last Posted Date: 2013-07-16

Lead Sponsor: XenoPort, Inc.

Target Recruit Count: 18

Registration Number: NCT01476124

Locations: 🇺🇸
GSK Investigational Site, Austin, Texas, United States

Effect of Mu-opioid Receptor Genetics on 3 Doses of Spinal Morphine for Postoperative Analgesia After Cesarean Section

Phase 4

Completed

Conditions: Postoperative Pain

Interventions: Drug: Morphine

First Posted Date: 2011-11-04

Last Posted Date: 2020-12-10

Lead Sponsor: Columbia University

Target Recruit Count: 169

Registration Number: NCT01465191

Locations: 🇺🇸
Columbia University Medical Center, New York, New York, United States
🇺🇸
George Washington University Medical Center, Washington, District of Columbia, United States